{
    "organizations": [],
    "uuid": "d21c0112fca7e2949b40c67c59b039078df3f5a8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-insmed-inc-submits-nda-to-fda-for/brief-insmed-inc-submits-nda-to-fda-for-alis-idUSASC09U6T",
    "ord_in_thread": 0,
    "title": "Insmed Inc Submits NDA To FDA For ALIS",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Insmed Inc:\n* INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC\n* INSMED - ANTICIPATES RECEIVING A SIX-MONTH PRIORITY REVIEW AND THAT NDA WILL BE REVIEWED BY DIVISION OF ANTI-INFECTIVE PRODUCTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T20:26:00.000+03:00",
    "crawled": "2018-03-30T12:45:37.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "insmed",
        "inc",
        "insmed",
        "submits",
        "new",
        "drug",
        "application",
        "fda",
        "ali",
        "ntm",
        "lung",
        "disease",
        "caused",
        "mac",
        "insmed",
        "anticipates",
        "receiving",
        "priority",
        "review",
        "nda",
        "reviewed",
        "division",
        "product",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}